Fig 1.
Schematic representation of the Markov model.
Table 1.
Model input parameters.
Table 2.
Model input parameters for the scenario analysis.
Table 3.
Deterministic result of the base-case analysis.
Table 4.
Deterministic result of the scenario analysis based on an effect duration of 11-year.
Fig 2.
Incremental cost-effectiveness ratio (ICER) for base-case based on HERA trial [5] and all scenarios[3].
Abbreviations: GDP: Gross domestic product; QALYs: Quality-adjusted life years.
Table 5.
Deterministic results for the scenario analysis based on a joint analysis from NSABP B-31 and NCCTG N9831 [3].
Fig 3.
Tornado diagram of one-way sensitivity analysis for the base case.
Abbreviations: DFS: Disease-free survival; HR: Hazard ratio; ICER: Incremental cost-effectiveness ratio; LRR: Locoregional recurrence; OS: Overall survival.
Fig 4.
Cost-effectiveness plane from the probabilistic sensitivity analysis based on 1,000 simulations.
Abbreviations: GDP: Gross domestic product; QALYs: Quality-adjusted life years.
Fig 5.
Cost-effectiveness acceptability curve for the base-case analysis.
Abbreviations: GDP: Gross domestic product.
Fig 6.
Cost-effectiveness acceptability curve for the scenario analysis based on a joint analysis from NSABP B-31 and NCCTG N9831[3].
Abbreviations: GDP: Gross domestic product; QALYs: Quality-adjusted life years.